Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $66.00

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) had its price objective lifted by research analysts at Oppenheimer from $55.00 to $66.00 in a report issued on Monday, The Fly reports. Oppenheimer’s price objective indicates a potential upside of 383.52% from the company’s current price.

A number of other analysts have also recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, March 17th. Zacks Investment Research upgraded shares of Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, February 24th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $48.00.

Shares of TARS traded down $4.66 during mid-day trading on Monday, reaching $13.65. 10,190 shares of the company’s stock were exchanged, compared to its average volume of 38,255. The stock’s fifty day simple moving average is $17.97. The stock has a market cap of $282.68 million, a PE ratio of -20.15 and a beta of 2.33. Tarsus Pharmaceuticals has a 52-week low of $14.41 and a 52-week high of $39.08.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last issued its quarterly earnings data on Monday, March 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 24.25% and a negative return on equity of 7.66%. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $7.11 million. On average, sell-side analysts forecast that Tarsus Pharmaceuticals will post -4.02 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Citigroup Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 123.0% in the 4th quarter. Citigroup Inc. now owns 2,145 shares of the company’s stock valued at $48,000 after buying an additional 1,183 shares during the period. Morgan Stanley purchased a new position in Tarsus Pharmaceuticals in the second quarter worth $241,000. Dimensional Fund Advisors LP acquired a new stake in Tarsus Pharmaceuticals in the fourth quarter valued at $202,000. Bank of America Corp DE boosted its position in shares of Tarsus Pharmaceuticals by 84.8% during the 4th quarter. Bank of America Corp DE now owns 10,662 shares of the company’s stock worth $240,000 after purchasing an additional 4,891 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth $289,000. 70.00% of the stock is owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Featured Stories

The Fly logo

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.